Case Title: Glaxo Group Limited Vs. Aubade Healthcare Private Limited and Anr.
Date of Order: 14.08.2025
Case Number: CS(COMM) 841/2025
Name of Court: High Court of Delhi
Name of Judge: Justice Manmeet Pritam Singh Arora
The plaintiff, Glaxo Group Limited, filed a suit seeking a permanent injunction to restrain the defendants from infringing its registered trademark ZENTEL and from passing off, along with claims for rendition of accounts and other reliefs. The matter relates to the plaintiff’s long-standing use and registration of the invented coined trademark ZENTEL for an antiparasitic pharmaceutical product launched globally in 1982 and in India since 1986, and alleges that the defendants adopted the visually and phonetically similar mark RENTEL for a medicinal product for hypertension, leading to potential consumer confusion and public health risks. The plaintiff discovered the defendants’ trademark application for RENTEL, issued a cease-and-desist notice, and indicated readiness for an amicable solution, but the defendants claimed bona fide adoption and denied similarity.
Procedurally, the court granted various procedural exemptions and directions for the plaint and documents, recognised the need for urgent interim relief waiving pre-litigation mediation, and registered the plaint. Observing the similarity between the marks and the non-prescription status of both products, the court found a prima facie case for the plaintiff and, considering balance of convenience and potential for irreparable harm, granted an ex-parte ad-interim injunction restraining the defendants from using the mark RENTEL or any deceptively similar mark for pharmaceutical products till the next date of hearing.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
Disclaimer: This information report is intended for informational purposes only and does not constitute legal advice.
